Interference of target protein translation in multivalent mRNA vaccine in cell-based assay
Journal of Pharmaceutical and Biomedical Analysis · 2026
DOI: 10.1016/j.jpba.2026.117526 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmaceutical and Biomedical Analysis, 2026. Verfasst von Alyssa Q Stiving und 7 weiteren Autor:innen. Beteiligte Einrichtung: Analytical Research and Development, Merck & Co., Inc., 126 E Lincoln Ave., Rahway, NJ 07065, USA. Hauptthemen laut MEDLINE: mRNA Vaccines, Protein Biosynthesis, RNA, Messenger. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Merck.
Abstract (Originalsprache)
Messenger RNA (mRNA) vaccines are highly effective against infectious diseases, but viral diversity has underscored the necessity for multivalent and combination vaccines. We hypothesize there could be interference of target protein translation in multivalent mRNA vaccines in cell-based assays used for potency testing. Following transfection into human cells, we observed that antigen protein translation is inhibited in multivalent formulations compared to their dose-matched monovalent counterparts using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Inhibited expression was further validated using Western blot and intra-cellular immunostaining with type-specific antibodies. Beyond direct antigen-specific analysis, LC-MS/MS proteomics data from the same assay without additional sample preparation provided a broad view of host cell responses, revealing proteome-level changes indicative of impaired global translation capacity in cells transfected with high dose mRNA(s). To the best of our knowledge, we report for the first time in literature that antagonistic interactions among mRNA constructs can reduce protein expression in multivalent drug products. Our study also demonstrates that LC-MS/MS is a viable alternative for potency testing without dependence on antibodies. These findings highlight the need for careful cell-based assay design, multivalent drug product reference standards for potency assessment, and deliberate mRNA dose optimization in multivalent formulations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Analytical Research and Development, Merck & Co., Inc., 126 E Lincoln Ave., Rahway, NJ 07065, USA.
- Analytical Research and Development, Merck & Co., Inc., 126 E Lincoln Ave., Rahway, NJ 07065, USA. Electronic address: hualin.li@merck.com.
- Analytical Research and Development, Merck & Co., Inc., 126 E Lincoln Ave., Rahway, NJ 07065, USA. Electronic address: xuanwen.li@merck.com.
Förderung
- Merck
Zitieren
APA
Stiving, A. Q., Dornadula, G., Roose, B. W., Gonzalez, A., Whiteman, M. C., Schuessler, H. A., Li, H. H., & Li, X. (2026). Interference of target protein translation in multivalent mRNA vaccine in cell-based assay. Journal of Pharmaceutical and Biomedical Analysis. https://doi.org/10.1016/j.jpba.2026.117526
Vancouver
Stiving AQ, Dornadula G, Roose BW, Gonzalez A, Whiteman MC, Schuessler HA, et al. Interference of target protein translation in multivalent mRNA vaccine in cell-based assay. Journal of Pharmaceutical and Biomedical Analysis. 2026. doi:10.1016/j.jpba.2026.117526
BibTeX
@article{Stiving2026,
author = {Stiving, Alyssa Q and Dornadula, Geethanjali and Roose, Benjamin W and Gonzalez, Ariel and Whiteman, Melissa C and Schuessler, Hillary A and Li, Hualin Helen and Li, Xuanwen},
title = {Interference of target protein translation in multivalent mRNA vaccine in cell-based assay},
journal = {Journal of Pharmaceutical and Biomedical Analysis},
year = {2026},
doi = {10.1016/j.jpba.2026.117526}
}
EUVIMED